Éric Chevalier

1.2k citations

30 papers · 892 indexed · h-index 20

Impact in

Immunology top 10%
- Immunotherapy and Immune Responses
Oncology
- Chemokine receptors and signaling

Papers in ⓘ

Immunology and Allergy 3
Hematology 5

Co-authors: Daniel P. Matton (3 shared papers)Daniel Obrecht (3 shared papers)Kerstin Moehle (2 shared papers)Klaus Dembowsky (8 shared papers)Pierre Rivière (2 shared papers)X. Pascaud (2 shared papers)Jean‐Louis Junien (2 shared papers)Xuesong Wu (1 shared paper)
Journals: Blood (3 papers)Bioorganic & Medicinal Chemistry Letters (3 papers)Circulation (2 papers)Gastroenterology (2 papers)Molecular Cancer Therapeutics (1 paper)
Partner nations: United States France Germany

In The Last Decade

Éric Chevalier

30 papers receiving 864 citations

Peers

Countries citing papers authored by Éric Chevalier

Since Specialization

Citations

This map shows the geographic impact of Éric Chevalier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Chevalier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Chevalier more than expected).

Fields of papers citing papers by Éric Chevalier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éric Chevalier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Chevalier. The network helps show where Éric Chevalier may publish in the future.

Co-authors

The 25 scholars most cited alongside Éric Chevalier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Éric Chevalier Line = papers co-authored together Éric Chevalier links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	C-X-C Motif Chemokine Receptor 4 Blockade Promotes Tissue Repair After Myocardial Infarction by Enhancing Regulatory T Cell Mobilization and Immune-Regulatory Function Circulation ·Yong Wang, Klaus Dembowsky, Éric Chevalier, Philipp Stüve, Mortimer Korf‐Klingebiel, Matthias Lochner, L. Christian Napp, Heike Frank, E Brinkmann, Anna Kanwischer, Johann Bauersachs, Mariann Gyöngyösi, Tim Sparwasser, Kai C. Wollert	2019	99
2	Cutting Edge: Chemoattractant Receptor-Homologous Molecule Expressed on TH2 Cells Plays a Restricting Role on IL-5 Production and Eosinophil Recruitment The Journal of Immunology ·Éric Chevalier, Jeff Stock, Timothy S. Fisher, Mathieu Dupont, Magali Fric, Helene Fargeau, Murielle Leport, Sylvain Soler, Fabien Schmidlin, Marie‐Pierre Pruniaux, Michel Fink, Claude Bertrand, John A. McNeish, Baiyong Li	2005	69
3	Fedotozine reverses ileus induced by surgery or peritonitis: Action at peripheral Κ-Opioid receptors Gastroenterology ·Pierre Rivière, X. Pascaud, Éric Chevalier, B. Le Gallou, Jean‐Louis Junien	1993	62
4	Chemokine Receptors as Targets for Cancer Therapy Current Pharmaceutical Design ·Xuesong Wu, Vivian C. Lee, Éric Chevalier, Sam T. Hwang	2009	54
5	Protein epitope mimetic macrocycles as biopharmaceuticals Current Opinion in Chemical Biology ·Anatol Luther, Kerstin Moehle, Éric Chevalier, Glenn E. Dale, Daniel Obrecht	2017	53
6	CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer Molecular Cancer Therapeutics ·Jingyu Xiang, Michelle A. Hurchla, Francesca Fontana, Xinming Su, Sarah R. Amend, Alison K. Esser, Garry J. Douglas, Chidananda Mudalagiriyappa, Kathryn E. Luker, Timothy Pluard, Foluso O. Ademuyiwa, Bárbara Romagnoli, Gérald Tuffin, Éric Chevalier, Gary D. Luker, Michael Bauer, Johann Zimmermann, Rebecca Aft, Klaus Dembowsky, Katherine N. Weilbaecher	2015	49
7	β-Hairpin protein epitope mimetic technology in drug discovery Drug Discovery Today Technologies ·Daniel Obrecht, Éric Chevalier, Kerstin Moehle, John A. Robinson	2011	48
8	ScRALF3, a secreted RALF‐like peptide involved in cell–cell communication between the sporophyte and the female gametophyte in a solanaceous species The Plant Journal ·Éric Chevalier, Audrey Loubert‐Hudon, Daniel P. Matton	2012	42
9	Cell–cell communication and signalling pathways within the ovule: from its inception to fertilization New Phytologist ·Éric Chevalier, Audrey Loubert‐Hudon, Erin Zimmerman, Daniel P. Matton	2011	41
10	Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial Journal of Translational Medicine ·Darja Karpova, Susanne Bräuninger, Eliza Wiercinska, Ariane Krämer, Belinda Stock, Jochen Graff, Hans Martin, Achim Wach, Christophe Escot, Garry J. Douglas, Bárbara Romagnoli, Éric Chevalier, Klaus Dembowski, Leon Hooftman, Halvard Bönig	2017	36
11	Involvement of prostaglandins and CGRP-dependent sensory afferents in peritoneal irritation-induced visceral pain Regulatory Peptides ·Nadine Friese, Laurent Diop, Éric Chevalier, F. Angel, Pierre Rivière, Svein G. Dahl	1997	36
12	Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma Oncotarget ·Amy Barone, Rajarshi Sengupta, Nicole M. Warrington, Erin N. Smith, Patrick Y. Wen, Rolf A. Brekken, Bárbara Romagnoli, Garry J. Douglas, Éric Chevalier, Michael Bauer, Klaus Dembowsky, David Piwnica‐Worms, Joshua B. Rubin	2014	35
13	Multifaceted C-X-C Chemokine Receptor 4 (CXCR4) Inhibition Interferes with Anti–Vascular Endothelial Growth Factor Therapy–Induced Glioma Dissemination American Journal Of Pathology ·Jean‐Pierre Gagner, Yasmeen Sarfraz, Valerio Ortenzi, Fawaz M. Alotaibi, Luis Chiriboga, Awab Tayyib, Garry J. Douglas, Éric Chevalier, Bárbara Romagnoli, Gérald Tuffin, Michel Schmitt, Guillaume Lemercier, Klaus Dembowsky, David Zagzag	2017	34
14	Efficacy of the Novel Antibiotic POL7001 in Preclinical Models of Pseudomonas aeruginosa Pneumonia Antimicrobial Agents and Chemotherapy ·Cristina Cigana, Francesca Bernardini, Marcella Facchini, Beatriz Alcalá-Franco, Camilla Riva, Ida De Fino, Alice S. Rossi, Serena Ranucci, Pauline E. Misson, Éric Chevalier, Maj Brodmann, Michel Schmitt, Achim Wach, Glenn E. Dale, Daniel Obrecht, Alessandra Bragonzi	2016	32
15	CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma Blood ·Abdel Kareem Azab, İlyas Şahin, Feda Azab, Michele Moschetta, Yuji Mishima, Nicholas Burwick, Johann Zimmermann, Bárbara Romagnoli, Kalpana Patel, Éric Chevalier, Aldo M. Roccaro, Irene M. Ghobrial	2014	29
16	Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: Metabolism-directed optimization studies towards orally bioavailable derivatives Bioorganic & Medicinal Chemistry Letters ·Fabrice Vergne, Patrick Bernardelli, Edwige Lorthiois, Nga Pham, Emmanuelle Proust, Chrystelle Oliveira, Abdel‐Kader Mafroud, Pierre Ducrot, Roger Wrigglesworth, Françoise Berlioz-Seux, Francis Coleon, Éric Chevalier, F. Moreau, Moulay Idrissi, Anita Tertre, Arnaud Descours, Patrick Berna, Mei Li	2004	28
17	Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives Bioorganic & Medicinal Chemistry Letters ·Patrick Bernardelli, Edwige Lorthiois, Fabrice Vergne, Chrystelle Oliveira, Abdel‐Kader Mafroud, Emmanuelle Proust, Nga Pham, Pierre Ducrot, F. Moreau, Moulay Idrissi, Anita Tertre, Bernadette Bertin, Magali Coupe, Éric Chevalier, Arnaud Descours, Françoise Berlioz-Seux, Patrick Berna, Mei Li	2004	24
18	The CXCR4 antagonist POL5551 is equally effective as sirolimus in reducing neointima formation without impairing re-endothelialisation Thrombosis and Haemostasis ·Karim Hamesch, Pallavi Subramanian, Xiaofeng Li, Klaus Dembowsky, Éric Chevalier, Christian Weber, Andreas Schober	2012	23
19	Personalised anti-inflammatory therapy for bronchiectasis and cystic fibrosis: selecting patients for controlled trials of neutrophil elastase inhibition ERJ Open Research ·Holly R. Keir, Christopher J. Fong, Megan Crichton, Philip Barth, Éric Chevalier, Gill Brady, Gwen Kennedy, Johann Zimmermann, P. L. B. Bruijnzeel, Alison Dicker, James D. Chalmers	2019	20
20	Plant bioactive peptides: an expanding class of signaling molecules Canadian Journal of Botany ·Hugo Germain, Éric Chevalier, Daniel P. Matton	2006	19

About Éric Chevalier

Éric Chevalier is a scholar working on Immunology and Allergy, Hematology, Immunology, Anesthesiology and Pain Medicine and Oncology, having authored 30 papers that have together received 892 indexed citations. Recurring topics across this work include Chemokine receptors and signaling (7 papers), Immune cells in cancer (5 papers), Plant Molecular Biology Research (3 papers), Pulmonary Hypertension Research and Treatments (3 papers), Asthma and respiratory diseases (3 papers), Immunotherapy and Immune Responses (3 papers), Neuropeptides and Animal Physiology (3 papers) and Plant Reproductive Biology (3 papers). The work is most often cited by research in Immunology (221 citations), Oncology (224 citations), Microbiology (43 citations), Gastroenterology (35 citations) and Molecular Biology (426 citations). Éric Chevalier has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Daniel P. Matton, Daniel Obrecht, Kerstin Moehle, Klaus Dembowsky, Pierre Rivière, X. Pascaud, Jean‐Louis Junien, Xuesong Wu, Sam T. Hwang and Bárbara Romagnoli. Their work appears in journals such as Blood, Bioorganic & Medicinal Chemistry Letters, Circulation, Gastroenterology and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact